Research Report University Hospital clinical trial AC-004-EU

Abstract

A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain amyloidosis

Keywords

• systemic light-chain AL amyloidosis
• Melphalan